US 12,433,866 B2
Lasofoxifene treatment of aromatase-resistant ER+ cancer
Barry Samuel Komm, Columbus, OH (US); and Geoffrey L. Greene, Chicago, IL (US)
Assigned to Sermonix Pharmaceuticals, Inc., Columbus, OH (US)
Filed by Sermonix Pharmaceuticals, Inc., Columbus, OH (US)
Filed on Jul. 4, 2024, as Appl. No. 18/764,277.
Application 18/764,277 is a continuation of application No. 18/661,498, filed on May 10, 2024, abandoned.
Application 18/661,498 is a continuation of application No. 18/325,883, filed on May 30, 2023, granted, now 12,023,321, issued on Jul. 2, 2024.
Application 18/325,883 is a continuation of application No. 17/989,382, filed on Nov. 17, 2022, abandoned.
Claims priority of provisional application 63/280,769, filed on Nov. 18, 2021.
Prior Publication US 2024/0358677 A1, Oct. 31, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/40 (2006.01); A61K 31/4155 (2006.01); A61K 45/06 (2006.01); A61P 35/00 (2006.01)
CPC A61K 31/40 (2013.01) [A61K 31/4155 (2013.01); A61K 45/06 (2013.01); A61P 35/00 (2018.01)] 30 Claims
 
1. A method of treating estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2−) breast cancer, the method comprising:
administering a therapeutically effective amount of lasofoxifene or a pharmaceutically acceptable salt thereof as adjuvant therapy to a female patient whose ER+/HER2− breast cancer has developed resistance to an aromatase inhibitor without having acquired a mutation in the ESR1 gene.